Johnson & Johnson - Search News

News

Johnson & Johnson, tariffs

Johnson & Johnson’s stock surges as tariff cost estimate slashed and profit outlook raised

Adjusted earnings per share for the quarter to June 29 fell to $2.77 from $2.82 in the same period a year ago, and topped the average analyst EPS estimate compiled by FactSet of $2.68.

Reuters on MSN · 2h

Johnson & Johnson lifts 2025 forecast, halves tariff cost outlook

By Michael Erman and Patrick Wingrove (Reuters) -Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and profit forecast on Wednesday after a strong quarter for flagship cancer drug Darzalex and its cardiovascular devices.

Seeking Alpha · 1h

Johnson & Johnson Q2 Earnings Review: This Is As Safe As Pharma Investing Gets

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my JNJ earnings update.

Mike Johnson calls for 'transparency' in Epstein case

NBC News on MSN · 5h

Mike Johnson calls for Epstein files and ICE memos gives deportation guidance: Morning Rundown

Donald Trump brushes off his supporters’ interest in the Jeffrey Epstein case, and House Speaker Mike Johnson speaks out.

USA TODAY on MSN · 16h

Mike Johnson calls for 'transparency' in Epstein case, in a break with Trump

The House Speaker said he is "for transparency," in a moves that breaks with Trump's calls to move on from the Epstein case review.

CBS News · 3h

Speaker Mike Johnson calls for transparency over Epstein documents

Speaker of the House Mike Johnson, an ally of President Trump, is another Republican who is now calling for greater transparency and the release of the Jeffrey Epstein documents. Johnson also said there needs to be more of an explanation from Attorney General Pam Bondi regarding her comments on the files as the issue divides the GOP.

3hon MSN

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants.

The drug and medical device maker Johnson & Johnson kicked off the healthcare earnings season with a better-than-anticipated ...

5hon MSN

Johnson & Johnson beats profit estimates on strong Darzalex, medtech sales

Johnson & Johnson raised its full-year sales forecast on Wednesday after beating estimates for second-quarter profit on ...

Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...

Johnson & Johnson leads S&P 500 and Dow

Johnson & Johnson is leading the S&P 500 and the Dow Jones Industrial Average after the drugmaker slashed its estimate for the impact of tariffs in 2025 and raised its outlook. The company’s stock is ...

8hon MSN

C.J. Gardner-Johnson: Eagles traded me because they’re scared of a competitor

C.J. Gardner-Johnson helped the Eagles win the Super Bowl in February, but he was traded to the Texans in March. And ...

Life-Extension Guru Bryan Johnson Says He Has Way More Microplastics in His Semen Than His Blood

Johnson shared yet another personal insight that nobody asked for: His jizz has substantially more microplastics in it than ...

3hon MSN

Democratic state Sen. Nathan Johnson announces run for Texas attorney general

The third-term Democrat from Dallas faces long odds in a state that has only elected Republicans to statewide office for ...

22hon MSN

Johnson & Johnson Q2 Preview: Focus on tariff threat, MedTech softness

Stay updated on Johnson & Johnson's Q2 earnings as it faces tariff threats, MedTech challenges, and legal risks.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Johnson & Johnson, tariffs

Mike Johnson calls for 'transparency' in Epstein case

Related topics